New hope for ovarian cancer: immune-boosting drug combined with chemo
NCT ID NCT02726997
First seen Nov 10, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-phase study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (carboplatin and paclitaxel) helps control advanced ovarian, fallopian tube, or primary peritoneal cancer. 18 women with stage III or IV cancer took part. The goal was to see how the treatment changes the immune system's response to the tumor, not to cure the disease. Results may guide future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III OVARIAN CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.